AZTA vs. FOLD, RNA, TWST, MOR, TGTX, IMCR, DNLI, ACLX, LFST, and NEOG Should you be buying Azenta stock or one of its competitors? The main competitors of Azenta include Amicus Therapeutics (FOLD), Avidity Biosciences (RNA), Twist Bioscience (TWST), MorphoSys (MOR), TG Therapeutics (TGTX), Immunocore (IMCR), Denali Therapeutics (DNLI), Arcellx (ACLX), LifeStance Health Group (LFST), and Neogen (NEOG). These companies are all part of the "medical" sector.
Amicus Therapeutics (NASDAQ:FOLD ) and Azenta (NASDAQ:AZTA ) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, community ranking, analyst recommendations, valuation and institutional ownership.
Amicus Therapeutics received 497 more outperform votes than Azenta when rated by MarketBeat users. Likewise, 73.50% of users gave Amicus Therapeutics an outperform vote while only 39.58% of users gave Azenta an outperform vote.
In the previous week, Amicus Therapeutics had 7 more articles in the media than Azenta. MarketBeat recorded 12 mentions for Amicus Therapeutics and 5 mentions for Azenta. Amicus Therapeutics' average media sentiment score of 0.73 beat Azenta's score of 0.46 indicating that Azenta is being referred to more favorably in the news media.
Azenta has a net margin of -23.12% compared to Azenta's net margin of -34.73%. Amicus Therapeutics' return on equity of 0.81% beat Azenta's return on equity.
Azenta has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.
99.1% of Azenta shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by insiders. Comparatively, 1.8% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Amicus Therapeutics presently has a consensus price target of $17.50, suggesting a potential upside of 82.86%. Azenta has a consensus price target of $68.40, suggesting a potential upside of 34.46%. Given Azenta's stronger consensus rating and higher possible upside, research analysts clearly believe Amicus Therapeutics is more favorable than Azenta.
Amicus Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Azenta has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
Summary Amicus Therapeutics and Azenta tied by winning 9 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding AZTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
